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Abstract
Nimustine (ACNU) and temozolomide (TMZ) are DNA alkylating agents which are commonly used in chemotherapy for
glioblastomas. ACNU is a DNA cross-linking agent and TMZ is a methylating agent. The therapeutic efficacy of these agents
is limited by the development of resistance. In this work, the role of the Fanconi anemia (FA) repair pathway for DNA






2/2 cells and their parental cells, and Chinese hamster ovary and lung fibroblast cells were used:
FANCD1/BRCA2mt, FANCG
2/2 and their parental cells. Cell survival was examined after a 3 h ACNU or TMZ treatment by
using colony formation assays. All FA repair pathways were involved in ACNU-induced DNA damage. However, FANCG and
FANCD1/BRCA2 played notably important roles in the repair of TMZ-induced DNA damage. The most effective molecular
target correlating with cellular sensitivity to both ACNU and TMZ was FANCD1/BRCA2. In addition, it was found that
FANCD1/BRCA2 small interference RNA efficiently enhanced cellular sensitivity toward ACNU and TMZ in human
glioblastoma A172 cells. These findings suggest that the down-regulation of FANCD1/BRCA2 might be an effective strategy
to increase cellular chemo-sensitization towards ACNU and TMZ.
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Introduction
High-grade gliomas pose a therapeutic challenge. Nimustine [1-
(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-ni-
trosourea; ACNU] and temozolo-mide (TMZ) are both DNA
alkylating agents which are commonly used for chemo-therapy in
the treatment of gliomas. In the past, nitrosourea drugs such as
ACNU in Japan and central Europe, or carmustine [1,3-bis(2-
chloroethyl)-1-nitrosourea; BCNU], in the United States were the
standard of care in addition to radiation [1,2]. This has changed
since TMZ was shown to deliver benefits which were accompanied
by lower levels of toxicity [3]. However, a recent meta-analysis also
suggested the existence of a significant survival gain with the use of
ACNU in newly diagnosed high-grade gliomas [4]. Even if these
alkylating agents are used for the treatment for high-grade
gliomas, the therapeutic efficacy of these agents is limited by the
development of resistance to these agents, and the underlying
mechanisms leading to the development of this resistance is still
unknown.
ACNU and TMZ modify DNA at oxygen or nitrogen atoms in
bases and oxygen atoms of phosphodiester bonds [5]. ACNU is a
chloroethylating agent. The primary killing lesion appears to be
the formation of O
6-chloroethylguanine (G) [5]. This adduct is
unstable, and undergoes intramolecular rearrangements leading to
an intermediary N
1-O
6-ethenoG and, in a second step, to N
1-G-N
3-
cytosine interstrand cross-links [5]. TMZ is classified as a
monofunctional alkylating agent which modifies nucleotides
through direct methylation, and the main killing lesion appears
to be the formation of O





through the action of O
6-methylG-DNA methyltransferase
(MGMT) [5]. Other than MGMT, increasing evidence implicates
the involvement of other kinds of repair pathways, for example,
base excision repair (BER), Fanconi anemia (FA) repair, or double
strand break (DSB) repair pathways which are involved in the
repair of DNA damage induced by alkylating agents [6–11]. FA is
characterized by developmental abnormalities, susceptibility to
certain cancers, and sensitivity to DNA-DNA crosslinking agents
[12]. Although the FA pathway was initially characterized in terms
of the repair of DNA cross-linking agents [12], additional studies
have disclosed an increasingly detailed involvement in general
recombination repair and in the resolution of replication arrest
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19659[13–15]. In the regulation of the FA pathway, thirteen FA genes
have been identified at present [12], but the exact mechanistic
function of many of these FA proteins remains to be elucidated.
FANCD1 has been identified as the breast cancer susceptibility
protein BRCA2 [16] which regulates RAD51 in homologous
recombination repair (HRR) [17]. The FA proteins (A, B, C, E, F,
G, L, and M), together with the novel FA family members,
FANCA associating Polypeptide (FAAP)24/100, are subunits of a
nuclear core complex required for the mono-ubiquitylation of
FANCD2 [18,19]. It has been established that FANCD2 and
other FA proteins, including FANCG, promote HRR [15,20–22].
The work described here was designed to clarify which
components in the FA repair pathways contribute significantly to
ACNU and TMZ sensitivity. The activity of individual compo-
nents of the FA repair pathway (FANCA, FANCC, FANCD1/
BRCA2, FANCD2, and FANCG) leading to the repair of DNA
damage induced by TMZ and ACNU was assessed using
clonogenic survival assays. The cells used in this study formed a
panel of mouse embryonic fibroblasts (MEF) and Chinese hamster
ovary (CHO) and lung fibloblast cells defective in specific
components in the FA repair pathways.
Next, to test whether the resulting observations were applicable
to glioma cells, targeted repair pathways were down-regulated
using small interference RNA (siRNA), and the sensitivity of
human glioblastoma A172 cells to ACNU and TMZ was
measured. DNA repair mechanisms which can be identified as
contributing to ACNU and TMZ resistance should provide tools
which could be applied to improve drug efficacy.
Materials and Methods
Cell lines
The fibroblasts from many kinds of knockout mouse of deficient






2/2 cells) and the wild-type mouse (FANCwt) [23] were
obtained from the Fanconi Anemia Cell Repository, Oregon
Health and Science Univ. (Portland, OR). The Chinese hamster
lung fibroblast cell lines used in this study were: V79 (FANCD1wt),
V-C8 (FANCD1mutant (mt)), V-C8+ FANCD1 (FANCD1revertant (rev),
V-C8 containing a BAC with the murine FANCD1/BRCA2 gene)
[24,25]. The CHO cell lines used in this study were: AA8
(FANCGwt), KO40 (FANCG
2/2), 40BP6 (FANCGrev, complement-
ed with genomic CHO FANCG) [26], and SPD8 [27].
Human glioblastoma A172 cells were purchased from the
American Type Culture Collection of Cell Cultures (Manassas,
VA). All Cells were cultured in DMEM-10 [Dulbecco’s modified
Eagle’s medium containing 10% (v/v) fetal bovine serum,
20 mmol/L 2-[4-(2-hydroxyethyl)-1-piperazinyl] ethanesulfonic
acid, penicillin (50 units/mL), streptomycin (50 mg/mL), and
kanamycin (50 mg/mL)]. The cells were cultured at 37uCi na
conventional humidified CO2 incubator.
Drug treatments
ACNU (Sigma Aldrich, Saint Louis, MO) was dissolved at a
stock concentration of 10 mM in sterile H2O. ACNU stock
solutions were stored at 220uC until used. TMZ (LKT
Laboratories Inc. St. Paul, MN) was dissolved at a stock
concentration of 100 mM in dimethylsulfoxide (DMSO). TMZ
stock solutions were stored at 280uC until used. Cells were grown
in medium containing ACNU or TMZ at various concentrations
for 3 h, and then rinsed twice with PBS. At each different point,
solution contains completely the same concentration of sterile
H2O or DMSO except ACNU or TMZ.
Cell survival
Cell survival was measured using a standard clonogenic survival
assay as previously described [28]. The sensitivity of each cell line
was assessed from its D50 value, i.e. from the ACNU or TMZ dose
which reduced cell survival to 50%. In order to accurately
compare sensitivities to ACNU or TMZ in the repair defective cell
lines, the relative D50 values were normalized using the D50 value
of the parental cell lines.
Recombination assays
SPD8 cells were grown in the presence of 5 mg/ml 6-
thioguanine in order to reduce the frequency of spontaneous
reversion prior to treatments. The protocol for the reversion assay
[27] with SPD8 cells began with the inoculation of flasks (75 cm
2)
with 1.5610
6 cells in DMEM 4 h prior to a 24 h treatment with
ACNU or TMZ in a 5% CO2 incubator. After treatment, the cells
were rinsed three times with 10 ml of PBS, and 30 ml of DMEM
was added to allow recovery for 48 h. The selection of revertants
was performed by plating three dishes/group (3610
5cells/dish) in
the presence of hypoxanthine-L-azaserine-thymidine (HAsT;
50 mM hypoxanthine, 10 mM L-azaserine, 5 mM thymidine).
The cells were grown for 12 days before fixation with methanol,
and then stained with a 2% Giemsa solution. For survival assay,
about 500 cells per dish were plated on two dishes each and
cultured 8 days. The cells were fixed and stained.
RNA interference
The siRNA sequence used for human FANCD1/BRCA2 was
AAC AAC AAU UAC GAA CCA AAC UU [29]. The siRNA
sequence of the non-specific negative control was the same as used
previously [8]. The siRNA duplexes were synthesized and
provided as a purified and annealed duplex by the Japan Bio
Services Co., Ltd. (Saitama, Japan). Human FANCD1/BRCA2
siRNA or a non-specific negative control siRNA was transfected
into human glioblatoma A172 cells as previously described [8].
The siRNA sequences against the target FANCD1/BRCA2 used
here are the most popular in the previous reports. The cells were
then trypsinized and plated for colony forming assays.
Western Blotting
Total cellular protein amounts were quantified with a Bio-Rad
protein assay kit (Bio-Rad Labs, Richmond, CA). Aliquots of
proteins (20 mg) were subjected to Western blot analyses. Total
cellular lysates were loaded onto 7% tris-glycine gels (Invitorogen),
separated by electrophoresis at a constant voltage (125 V) and
electro-transferred onto nitrocellulose membranes at 42 V.
Membranes were blocked for 1 h at room temperature in blocking
buffer (25 mM Tris pH 8.0, 125 mM NaCl, 1% Tween 20 [TBS-
T buffer] containing 5% skim milk) and incubated with mouse
monoclonal anti- FANCD1/BRCA2 antibody (Ab-4, Calbiochem
and Oncogene, Calbiochem, Germany) or goat polyclonal anti-
actin antibody (I-19; Santa Cruz Biotechnology, Santa Cruz, CA)
for primary antibody for 2 h at room temperature. The
membranes were washed with TBS-T buffer three times and
incubated with a secondary antibody conjugated to horseradish
peroxidase for 1 h. After washing three times, the blots were
visualized by enhanced chemiluminescence method (GE Health-
care UK, Buckinghamshire, England) under the manufacturer’s
protocol. The amounts of the proteins in the samples were
quantified by scanning profiles using the Scion imaging program
(Scion, Frederick, MD). The relative ratio of the two bands to
illustrate the intensity of FANCD1/BRCA2 protein expression is
the average from triple experiments as measured by densitometry
FANCD1/BRCA2 Repair of ACNU- or TMZ-DNA Damage
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e19659following b-actin normalization with and without FANCD1/
BRCA2 siRNA. The inserted photo is typical.
MTS assay
A172 cells were plated into 96-well flat tissue-culture
microplates (Falcon) at a density of 2610
3cells/50 ml/well and
incubated at 37uCi n5 %C O 2 incubator. After a 6 h
incubation, 50 mlo fa nA C N Uo rT M Zs o l u t i o na taf i n a l
concentrations of 50, 150, 300, or 500 mM, was added to
individual wells, and the plates were incubated for an additional
3 days. On day 3, 20 ml of an MTS solution (CellTiter 96
Aqueous One Solution Cell Proliferation Assay; Promega Co.,
Madison, WI) was added to each well, and plates were
incubated for a further 2 h following the manufacturer’s
protocol. The optical density at 492 nm was measured with a
Microplate Reader (Multiskan FC; Thermo Fisher Scientific
Inc., Waltham, MA). The results were shown as a percentage
cell growth calculated as follows: % cell growth=(optical
density of an ACNU-treated or TMZ-treated well2optimal
density of cell-free control)/(optical density of cell-only con-
trol2optimal density of cell-free control)6100.
Immunocytochemistry
Cells were grown on cover-glasses in 30 mm dish, fixed in 2%
paraformaldehyde in PBS for 15 min at room temperature and
washed in PBS. Then the cells were permeabilized for 5 min at
4uC in 0.2% Triton X-100, and blocked in PBS with 1% Bovine
Serum Albumin (BSA) for 1 h at 37uC. Cells were then incubated
with the rabbit polyclonal anti-Rad51 primary antibody (H-92,
Santa Cruz) for 1 h at room temperature at 1:300 dilutions in
PBS containing 1% BSA, and washed three times in PBS
containing 1% BSA for 10 min. The cells were incubated with
Alexa Fluor 488-conjugated secondary antibody (Molecular
Probes, Eugene, OR) for 1 h at room temperature at 1:400
dilutions in PBS containing 1% BSA, and washed three times for
10 min in PBS. Cover-glasses were mounted at 1:1000 dilutions
of 4,6-diamidino-2-phenylindole. Fluorescence images were
captured using a fluorescence microscope (Keyence, Tokyo,
Japan) for analysis.
Statistical analysis
Statistical analysis was performed using the Student’s t test.
Results
Repair genes which respond to ACNU-induced DNA
damage
Cellular responses to ACNU were examined by using FA
defective cells and their parental cells. As expected, all repair
defective cells were more sensitive to ACNU (a cross-linking agent)
than their parental cells (Fig. 1a–d). In particular, FANCG
2/2 and
FANCD1mt cells exhibited a striking hypersensitivity to ACNU.
Repair genes which respond to TMZ-induced DNA
damage
Cellular responses to TMZ were examined by using FA






comparable to their parental cells (Fig. 2a). On the other hand,
FANCD2
2/2, FANCD1mt, and FANCG
2/2 cells were more
sensitive to TMZ than their parental cells (Figs. 2a–d). As seen
in the responses to ACNU, FANCD1mt and FANCG
2/2 cells
exhibited a striking hypersensitivity to TMZ.
Relative contributions of FA components to ACNU and
TMZ sensitivity
The relative D50 values, listed sequentially in the order in which









2/2 cells (0.53) (Fig. 3). The relative D50 values listed in a








2/2 cells (0.82) (Fig. 3).
From statistic analysis to ACNU, P,0.01 was between FANCwt
and FANCA
2/2 or FANCC
2/2; P,0.001 was between FANCwt
and FANCD2
2/2, FANCwt and FANCG
2/2, FANCwt and
FANCD1mt. To TMZ, P,0.01 was between FANCwt and
FANCG
2/2, FANCwt and FANCD1mt.
Frequency of homologous recombination induced by
ACNU or TMZ
Since HRR follows the FA repair pathway through the step
involving FANCD1/BRCA2, it was of interest to know if HR in
SPD8 cells was specifically induced by ACNU or TMZ. As a
positive control, high HR frequencies were detected as 36.7 with
Camptothecin (100 nM) with treatment for 24 h. In the case of
ACNU and TMZ, HRR was obviously induced. After 10 mM and
30 mM ACNU treatments, the HR frequencies were 7.2-fold and
13.9-fold high, respectively, as compared with the control cells
without ACNU treatment. After 100 mM and 300 mM TMZ
treatments, on the other hand, the HR frequencies were 8.4-fold
and 22.8- fold high, respectively (Fig. 4 a). We plotted the
recombination frequency against the surviving fraction of SPD8
cells when exposed to varying concentrations of ACNU or TMZ.
At 50% survival, HR frequencies with TMZ were about 2 times
higher than those with ACNU (Fig. 4 b).
Effect of FANCD1/BRCA2 siRNA on ACNU or TMZ
sensitivity in A172 glioblastoma cells
To test whether this result was pertinent to chemotherapy
agents used against glioblastomas, FANCD1/BRCA2 expression
was silenced using siRNA in A172 glioblastoma cells, and
clonogenic survival assays and MTS assays were then performed
with these cells. A172 cells were transfected with FANCD1/BRCA2
siRNA for 48 h, and the expression of the protein was observed
using Western blot analysis (Fig. 5a). The level of FANCD1/
BRCA2 protein decreased to 29% when compared with the
negative controls. After 5 mM and 10 mM ACNU treatments,
FANCD1/BRCA2 silencing caused a 64% and 90% reduction in
colony formation when compared to cells transfected with the
negative control siRNA (Fig. 5b). In addition, after a 5 mMo r
10 mM TMZ treatment, FANCD1/BRCA2 silencing caused 75%
and 95% reductions in colony formation, respectively, when
compared to cells transfected with the negative control siRNA
(Fig. 5b). Similarly, after 50 mM and 150 mM ACNU treatments,
FANCD1/BRCA2 silencing caused a 57% and 38% reduction in
cell growth when compared to cells transfected with the negative
control siRNA (Fig. 5c). In addition, after 150 mM and 300 mM
TMZ treatments, FANCD1/BRCA2 silencing caused a 50% and
70% reduction, respectively in cell growth when compared to cells
transfected with the negative control siRNA (Fig. 5c).
Impaired Rad51 recombinase activity following FANCD1/
BRCA2 down-regulation
We detected apparent Rad51 foci in the nucleus of cells
transfected with the negative control siRNA from 12 h to 36 h
FANCD1/BRCA2 Repair of ACNU- or TMZ-DNA Damage
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Rad51 foci in the cells transfected with FANCD1/BRCA2 siRNA
before and after ACNU or TMZ treatment. We, however, found
Rad51 positive stain in cytoplasm alone (Fig. 6a). The number of
cells with more than five Rad51 foci per nucleus was lower in the
FANCD1/BRCA2 siRNA transfected cells than the negative control
siRNA transfected cells at 12 h, 24 h, and 36 h after ACNU or
TMZ treatment (Fig. 6b).
Discussion
It has been previously shown that the FA pathway confers
glioma resistance to DNA alkylating agents (TMZ and BCNU)
and inhibition of FA pathway causes increased sensitivity to TMZ
and BCNU [7]. Further, we examined in detail which components
in the FA repair pathways contribute significantly to ACNU and
TMZ sensitivity. Since the comparison of results between multiple
cell lines of different species and different degrees of transforma-
tion may be worrisome part in the present manuscript, we
compared each repair defective cell line at relative D50 values
(Fig. 3). At least, the genetic background of FANCAwt, FANCCwt,
FANCA/Cwt and FANCD2wt were almost the same, therefore, it is
definitely clear that ACNU-induced DNA-DNA cross-links might
be repaired by FANCA, FANCC and FANCD2 which are
components of FA nuclear core complex. This repair activity may
function in similar manner as it does for the repair of damage
caused by other cross-linking agents such as mitomycin C [12]. On
the other hand, FANCA and FANCC might play a minor role in
repair pathways for TMZ-induced DNA damage (Figs. 1–3),
therefore this DNA damage is suggested to be repaired through
nuclear core complex independent pathways. For both ACNU-
and TMZ-induced DNA damage, FANCD2, and in particular,
FANCG and FANCD1/BRCA2, play important roles (Figs. 1–3).
These results are in agreement with previous studies which
examined the sensitivity of these cells to other cross-linking agents
(mitomycin C), methylating agents [methyl methanesulfonate
(MMS)], or TMZ [11,24,26]. Recently, it was found that
FANCD2 interacts with FANCD1/BRCA2 independently of the
Figure 1. Sensitivity to ACNU. a, FANCwt cells (open circles), FANCA
2/2C
2/2 cells (closed triangles), FANCC
2/2 cells (closed squares), and FANCA
2/2
cells (closed circles); b, FANCwt cells (open circles) and FANCD2
2/2 cells (closed circles); c, FANCGwt cells (open circles), FANCGrev cells (closed triangles),
and FANCG
2/2 cells (closed circles); d, FANCD1wt cells (open circles), FANCD1rev cells (closed triangles), and FANCD1mt cells (closed circles). Each point
represents the mean of three independent experiments; bars indicate the SD.
doi:10.1371/journal.pone.0019659.g001
Figure 2. Sensitivity to TMZ. a, FANCwt cells (open circles), FANCA
2/2C
2/2 cells (closed triangles), FANCC
2/2 cells (closed squares), and FANCA
2/2
cells (closed circles); b, FANCwt cells (open circles) and FANCD2
2/2 cells (closed circles); c, FANCGwt cells (open circles), FANCGrev cells (closed
triangles), and FANCG
2/2 cells (closed circles); d, FANCD1wt cells (open circles), FANCD1rev cells (closed triangles), and FANCD1mt cells (closed circles).
Each point represents the mean of three independent experiments; bars indicate the SD.
doi:10.1371/journal.pone.0019659.g002
FANCD1/BRCA2 Repair of ACNU- or TMZ-DNA Damage
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which is independent from its role in the FA nuclear core complex.
Once FANCG is phosphorylated at Serine 7, it forms a complex
comprising FANCD1/BRCA2-FANCD2-FANCG-XRCC3 (D1-
D2-G-X3) which promotes HRR [30]. Other previous studies
reported FA pathway promotes HRR [14,15,20–22]. In this study,
following the notice that FANCD2, FANCG and FANCD1/
BRCA2 might be involved in repair of both ACNU and TMZ
(Figs. 1–3), it was also confirmed, using recombination assays, that
the HRR pathway was active after ACNU and TMZ treatments
(Fig. 4). If O
6-methylG which is induced by TMZ and O
6-
chloroethylG which is induced by ACNU are not repaired by
MGMT, they result in replication arrest and finally lead to DSBs.
In case of TMZ, other DNA methylation, i. e. N-alkylation may
also arrest replication forks as shown in MMS [31]. It is indicated
that DSBs were formed in response to ACNU or TMZ by
monitoring the expression of phosphorylated H2AX (cH2AX) [8–
10]. Therefore it is assumed that the HRR activity was proposed
as a repair mechanism for DSBs induced by ACNU or TMZ. It is
suggested that FANCD1/BRCA2 for HRR contributes predom-
inantly for repair of ACNU- and TMZ-induced DSBs (Fig. 3).
From these results of this and other reports, a model for repair is
suggested and a schematic drawing of this model is shown in Fig. 7.
It is possible that other FANC proteins which we didn’t examine
here play some roles in repair processes for these alkylating agents.
For example, the FANCF deficient ovarian tumor cell line,
2008+vector cells exhibited an approximately a two- to three-fold
decrease in survival as compared to the FA proficient
2008+FANCF cells to BCNU or TMZ [7]. FANCI is also
monoubiquitinated based on nuclear core complex and interacts
to form complex with FANCD2 [32]. The function of FANCI has
not been well known yet, but it is supposed to play significant role
in activation of FANCD2 and cooperate with FANCD2 in DNA
repair. FANCJ which is identical with BRCA1-associating C-
terminal helicase 1 (BACH1) or BRCA-interacting protein 1
(BRIP1) is supposed to associate with FA proteins or BRCA1
protein and function as a helicase for arrested replication fork
independent of FA nuclear core complex [33]. Other FA nuclear
complex proteins, for instance FANCL (an E3 ligase) which gives
ubiquitination to FANCD2 [34], FANCM (a homologue of DNA
helicase Hef in E. coli) [35] and, in addition, FAAP24 which
interacts with FANCM [18] might affect repair for DNA damage
induced by these alkylating agents. FANCN/partner of localizer of
BRCA2 (PALB2) is expected to play as a critical role as FANCD1/
BRAC2 in repair for DNA damage by ACNU or TMZ [36]
independent of nuclear core complex.
Figure 3. Relative D50 values (% compared to proficient cells)
for ACNU (open columns) and TMZ (closed columns). Two
asterisks (**), P,0.01; three asterisks (***), P,0.001.
doi:10.1371/journal.pone.0019659.g003
Figure 4. Homologous recombination in SPD8 cells. a, the reversion frequency from a non-functional to a functional hprt gene, giving
resistance to HaST following a 24 h treatment with ACNU (10 mM and 30 mM, striped columns) or TMZ (100 mM and 300 mM, closed columns) is
shown. Control, open column. Two asterisks (**), P,0.01; three asterisks (***), P,0.001. b, recombination frequency against the surviving fraction of
cells following a 24 h treatment with ACNU (10 mM and 30 mM, striped circles) or TMZ (100 mM and 300 mM, closed squares). Control, open square.
doi:10.1371/journal.pone.0019659.g004
FANCD1/BRCA2 Repair of ACNU- or TMZ-DNA Damage
PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19659It was shown that the siRNA for FANCD1/BRCA2 gene down-
regulated and increased the sensitivity of glioblastoma A172 cells
to both ACNU and TMZ (Fig. 5a, b). FANCD1/BRCA2 down-
regulation impaired Rad51 foci formation in HRR (Fig. 6 a, b).
Therefore, it is suggested that Rad51 function requires FANCD1/
BRCA2 activity in the HRR for DNA damage induced with
Figure 5. siRNA silencing of FANCD1/BRCA2 in glioblastoma A172 cells after ACNU and TMZ treatments. a, expression analysis of
FANCD1/BRCA2 in cells transfected with siRNA for human FANCD1/BRCA2 or the negative control siRNA using Western blots. Actin was used as a
loading control, and the relative ratios of protein were normalized using actin levels. b, effect of siRNA silencing of FANCD1/BRCA2 on cellular
sensitivity to ACNU and TMZ. c, effect of siRNA silencing of FANCD1/BRCA2 on cell growth after ACNU or TMZ treatment. Open columns, negative
control siRNA; closed columns, FANCD1/BRCA2 siRNA. Columns show the mean of three independent experiments; the bars indicate the SD. An
asterisk (*) indicates significant difference (P,0.05). Two asterisks (**), P,0.01; three asterisks (***), P,0.001.
doi:10.1371/journal.pone.0019659.g005
Figure 6. Rad51 foci formation in glioblastoma A172 cells after ACNU and TMZ treatments. a, typical photo. b, open columns, negative
control siRNA; closed columns, FANCD1/BRCA2 siRNA. Columns show the mean of two independent experiments; bars indicate the SD.
doi:10.1371/journal.pone.0019659.g006
FANCD1/BRCA2 Repair of ACNU- or TMZ-DNA Damage
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19659ACNU and TMZ. These results come to the conclusion that
FANCD1/BRCA2 down-regulation could be a potentially useful
strategy for enhancing the therapeutic effects of not only ACNU
but also of TMZ, in treatments for glioma cells. Of course, when
applied as a therapy, such chemo-sensitization must be delivered
selectively to the tumor cells, since normal tissues could also
depend on the same DNA repair pathway. Novel chemothera-
peutic approaches utilizing loco-regional delivery have recently
been shown to improve the survival of glioma patients [37].
Therefore, the combination of such a loco-regional delivery system
and the simultaneous down-regulation of FANCD1/BRCA2
could be an effective tool to enhance chemotherapy results for
glioma patients. The abnormalities of FANCD1/BRCA2 gene have
been reported in other cancer cells such as breast or ovarian
cancer cells [12]. Therefore, ACNU and TMZ might be efficient
for them. On the other hand, it is possible that nonhomologous
end-joining repair might be predominant with error-prone under
the depression of HRR after treatments with ACNU and TMZ in
gliomas.
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